Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study

被引:17
作者
Ueoka, H
Tabata, M
Kiura, K
Shibayama, T
Gemba, K
Segawa, Y
Chikamori, K
Yonei, T
Hiraki, S
Harada, M
机构
[1] Okayama Univ, Sch Med, Dept Med 2, Okayama 7008558, Japan
[2] Natl Shikoku Canc Ctr, Dept Med, Matsuyama, Ehime 7900007, Japan
[3] Okayama Rosai Hosp, Dept Med, Okayama 7028055, Japan
[4] Natl Okayama Hosp, Dept Resp Med, Okayama 7000807, Japan
[5] Okayama Red Cross Hosp, Dept Med, Okayama 7000941, Japan
关键词
phase I study; irinotecan; cisplatin; small-cell lung cancer; non-small-cell lung cancer;
D O I
10.1038/sj.bjc.6690157
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-II to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease or small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m(-2) and given by l-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m(-2), and the dose was escalated by an increase of 10 mg m(-2). The maximally tolerated dose of CPT-II was determined as 60 mg m(-2) because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 1:100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m(-2) and 60 mg m(-2) respectively.
引用
收藏
页码:984 / 990
页数:7
相关论文
共 20 条
  • [1] Aoe K., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P15
  • [2] BONOMI P, 1996, LUNG CANC PRINCIPLES, P811
  • [3] FUJIWARA Y, 1994, P AN M AM SOC CLIN, V13, P335
  • [4] A PHASE-II STUDY OF CPT-11, A NEW DERIVATIVE OF CAMPTOTHECIN, FOR PREVIOUSLY UNTREATED NON-SMALL-CELL LUNG-CANCER
    FUKUOKA, M
    NIITANI, H
    SUZUKI, A
    MOTOMIYA, M
    HASEGAWA, K
    NISHIWAKI, Y
    KURIYAMA, T
    ARIYOSHI, Y
    NEGORO, S
    MASUDA, N
    NAKAJIMA, S
    TAGUCHI, T
    ASAKAWA, M
    NAKABAYASI, T
    NAKAI, T
    KURITA, Y
    KINAMERI, K
    NOMURA, K
    NAGAO, K
    SAIJO, N
    OHE, Y
    SUGIURA, T
    SHIMOKATA, K
    SAKA, H
    NEGORO, S
    NAKAJIMA, S
    TOHDA, Y
    FUJII, M
    OTA, M
    HARA, N
    HARA, Y
    FUJISAWA, K
    NAKANO, S
    ARAKI, J
    NIITANI, H
    MIYATA, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 16 - 20
  • [5] CISPLATIN DOSE INTENSITY IN NON-SMALL CELL LUNG-CANCER - PHASE-II RESULTS OF A DAY-1 AND DAY-8 HIGH-DOSE REGIMEN
    GANDARA, DR
    WOLD, H
    PEREZ, EA
    DEISSEROTH, AB
    DOROSHOW, J
    MEYERS, F
    MCWHIRTER, K
    HANNIGAN, J
    DEGREGORIO, MW
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (10) : 790 - 794
  • [6] EVALUATION OF CISPLATIN INTENSITY IN METASTATIC NON-SMALL-CELL LUNG-CANCER - A PHASE-III STUDY OF THE SOUTHWEST-ONCOLOGY-GROUP
    GANDARA, DR
    CROWLEY, J
    LIVINGSTON, RB
    PEREZ, EA
    TAYLOR, CW
    WEISS, G
    NEEFE, JR
    HUTCHINS, LF
    ROACH, RW
    GRUNBERG, SM
    BRAUN, TJ
    NATALE, RB
    BALCERZAK, SP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) : 873 - 878
  • [7] CISPLATIN AND VINDESINE COMBINATION CHEMOTHERAPY FOR ADVANCED-CARCINOMA OF THE LUNG - A RANDOMIZED TRIAL INVESTIGATING 2 DOSAGE SCHEDULES
    GRALLA, RJ
    CASPER, ES
    KELSEN, DP
    BRAUN, DW
    DUKEMAN, ME
    MARTINI, N
    YOUNG, CW
    GOLBEY, RB
    [J]. ANNALS OF INTERNAL MEDICINE, 1981, 95 (04) : 414 - 420
  • [8] HSIANG YH, 1988, CANCER RES, V48, P1722
  • [9] KANEDA N, 1990, CANCER RES, V50, P1715
  • [10] ENHANCED ANTITUMOR EFFICACY OF A COMBINATION OF CPT-11, A NEW DERIVATIVE OF CAMPTOTHECIN, AND CISPLATIN AGAINST HUMAN LUNG-TUMOR XENOGRAFTS
    KUDOH, S
    TAKADA, M
    MASUDA, N
    NAKAGAWA, K
    ITOH, K
    KUSUNOKI, Y
    NEGORO, S
    MATSUI, K
    TAKIFUJI, N
    MORINO, H
    FUKUOKA, M
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1993, 84 (02): : 203 - 207